세계의 환각제 시장 분석(2022년)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 환각제 시장은 2021년 36억 2,000만 달러에서 2022년 41억 9,000만 달러로 15.6%의 CAGR로 성장할 것으로 예측됩니다. 환각제 시장은 14.2%의 CAGR로 성장해 2026년 70억 3,000만 달러에 달할 것으로 예측됩니다.

2021년 환각제 시장에서는 북미가 가장 큰 지역이 되었습니다. 아시아태평양은 예측 기간 동안 가장 성장하는 지역으로 예상됩니다.

정신 질환(고통, PTSD 등) 사례 증가는 앞으로 환각제 시장 성장을 촉진할 것으로 예상됩니다. 정신약은 우울증과 외상 후 스트레스 장애를 치료하는데 사용되며, 일반적으로 정신 질환을 줄입니다.

우울증 스프레이 약물 출현은 환각제(Psychedelic Drugs) 시장이 인기를 얻고 있는 주요 요인입니다. 환각제 시장에서 사업을 전개하는 주요 기업은 시장의 입지를 유지하기 위해 우울증 장애 비강 스프레이 약물을 도입하고 있습니다.

목차

제1장 주요 요약

제2장 환각제 시장 특징

제3장 환각제 시장 경향과 전략

제4장 환각제 시장 :신종 코로나 바이러스 감염증(COVID-19) 영향

제5장 환각제 시장 : 시장 규모·성장률

• 과거 시장(단위 : 10억 달러, 2016-2021년)
  • 시장 촉진 요인
  • 시장 억제 요인
• 시장 예측(단위 : 10억 달러, 2021-2026년, 2031년)
  • 시장 촉진 요인
  • 시장 억제 요인

제6장 환각제 시장 내역

• 종류별 시장 구분(단위 : 10억 달러, 2016-2021년, 2021-2026년, 2031년)
  • 리젤긴산디에틸아미드(LSD)
  • 케타민
  • 펜시클리딘
  • 감마하이드록시부티르산(GHB)
  • 샐비어
• 적응증별 시장 구분(단위 : 10억 달러, 2016-2021년, 2021-2026년, 2031년)
  • 우울
  • PTSD
• 원료별 시장 구분(단위 : 10억 달러, 2016-2021년, 2021-2026년, 2031년)
  • 자연
  • 합성
• 용도별 시장 구분(단위 : 10억 달러, 2016-2021년, 2021-2026년, 2031년)
  • 치료 저항성 우울증
  • 아편 중독
  • 외상 후 스트레스 장애(PTSD)
  • 나루코렙시
  • 공황장애
• 유통 채널별 시장 구분(단위 : 10억 달러, 2016-2021년, 2021-2026년, 2031년)
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제7장 환각제 시장 : 지역별·국가별 분석

• 지역별 시장 구분(단위 : 10억 달러, 2016-2021년, 2021-2026년, 2031년)
• 국가별 시장 구분(단위 : 10억 달러, 2016-2021년, 2021-2026년, 2031년)

제8장 아시아태평양 환각제 시장

• 시장 개요
• 지역 정보
• 종류별 시장 구분(단위 : 10억 달러, 2016-2021년, 2021-2026년, 2031년)
• 용도별 시장 구분(단위 : 10억 달러, 2016-2021년, 2021-2026년, 2031년)

제9장 중국의 환각제 시장

제10장 인도의 환각제 시장

제11장 일본의 환각제 시장

제12장 호주의 환각제 시장

제13장 인도네시아의 환각제 시장

제14장 한국의 환각제 시장

제15장 서구의 환각제 시장

제16장 영국의 환각제 시장

제17장 독일의 환각제 시장

제18장 프랑스의 환각제 시장

제19장 동유럽의 환각제 시장

제20장 러시아의 환각제 시장

제21장 북미의 환각제 시장

제22장 미국의 환각제 시장

제23장 남미의 환각제 시장

제24장 브라질의 환각제 시장

제25장 중동의 환각제 시장

제26장 아프리카의 환각제 시장

제27장 환각제 시장 : 경쟁 상황과 기업 프로필

• 환각제 시장 : 경쟁 상황
• 환각제 시장 : 기업 프로필
  • Johnson& Johnson
  • Pfizer
  • Hikma Pharmaceuticals PLC
  • Roche Holding AG
  • Merck& Co Inc

제28장 환각제 시장의 주요 기업 합병·인수(M&A)

제29장 환각제 시장 : 장래 전망과 잠재 분석

제30장 부록

“Psychedelic Drugs Global Market Report 2022” from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global psychedelic drugs market.

This report focuses on psychedelic drugs market which is experiencing strong growth. The report gives a guide to the psychedelic drugs market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.

• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.

• Create regional and country strategies on the basis of local data and analysis.

• Identify growth segments for investment.

• Outperform competitors using forecast data and the drivers and trends shaping the market.

• Understand customers based on the latest market research findings.

• Benchmark performance against key competitors.

• Utilize the relationships between key data sets for superior strategizing.

• Suitable for supporting your internal and external presentations with reliable high quality data and analysis

• Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Where is the largest and fastest growing market for the psychedelic drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The Psychedelic Drugs market global report” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider psychedelic drugs market, and compares it with other markets.

• The market characteristics section of the report defines and explains the market.

• The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.

• Market segmentations break down market into sub markets.

• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.

• Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

• The psychedelic drugs market section of the report gives context. It compares the psychedelic drugs market with other segments of the psychedelic drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, psychedelic drugs indicators comparison.

Scope

Markets Covered:

• 1) By Type: Lysergic Acid Diethylamid (LSD); Ketamine; Phencyclidine; Gamma Hydroxybutyric Acid (GHB); Salvia

• 2) By Disease Indication: Depression; PTSD

• 3) By Origin: Natural; Synthetic

• 4) By Application: Treatment-Resistant Depression; Opiate addiction; Post- Traumatic Stress Disorder; Narcolepsy; Panic Disorders

• 5) By Distribution Channel: Hospitals Pharmacy; Retail Pharmacy; Online Pharmacy

• Companies Mentioned: Johnson & Johnson; Pfizer; Hikma Pharmaceuticals PLC; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.

• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

• Time series: Five years historic and ten years forecast.

• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Executive Summary

Major players in the psychedelic drug market are: Johnson & Johnson, Pfizer, Hikma Pharmaceuticals PLC, Roche Holding AG, Merck & Co Inc, Jazz Pharmaceuticals plc, COMPASS Pathways PLC, Celon Pharma S.A., Numinus Wellness Inc, AbbVie, Mylan N.V., Avadel, NeuroRx Inc., Klarisana, AstraZeneca, Dr. Reddy's Laboratories Ltd, Takeda Pharmaceutical Company Limited, Allergan Inc, Mota Ventures Corp., Seelos Therapeutics, Emmes Company, and Novatris International AG.

The global psychedelic drugs market is expected to grow from $3.62 billion in 2021 to $4.19 billion in 2022 at a compound annual growth rate (CAGR) of 15.6%. The psychedelic drugs market is expected to reach $7.03 billion in 2026 at a CAGR of 14.2%.

The psychedelic drug market consists of sales of psychedelic drugs by entities (organizations, sole traders, and partnerships) that are used to treat depression and post-traumatic stress disorder and also help with mental health diagnoses. Psychedelic drugs refer to hallucinogens. These drugs are a group of substances that usually alter and enhance perception, thinking processes, energy levels, and promote mental experiences. These include chemicals such as Lysergic acid diethylamid (LSD) and plants such as peyote. These medications are used to treat a variety of brain conditions.

The main types of psychedelic drugs are lysergic acid diethylamid, ketamine, phencyclidine, gamma-hydroxybutyric acid (GHB), and salvia. Lysergic Acid Diethylamide (LSD) is also known colloquially as acid. LSD is manufactured in crystalline form and then mixed with other inert ingredients or diluted as a liquid to produce an ingestible form. The various disease indications include depression and PTSD, which could be natural or synthetic. The numerous applications include treatment-resistant depression, opiate addiction, post-traumatic stress disorder, narcolepsy, and panic disorders, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

North America was the largest region in the psychedelic drug market in 2021. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psychedelic drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The psychedelic drugs market research report is one of a series of new reports from The Business Research Company that provides psychedelic drug market statistics, including psychedelic drug industry global market size, regional shares, competitors with a psychedelic drug market share, detailed psychedelic drug market segments, market trends and opportunities, and any further data you may need to thrive in the psychedelic drugs industry. This psychedelic drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The increase in the cases of mental illnesses is expected to propel the growth of the psychedelic drug market going forward. Mental illnesses refer to health conditions involving changes in emotion, thinking, or behavior. Mental illnesses include conditions such as distress and post-traumatic stress disorder. Psychedelic drugs are used to treat depression and post-traumatic stress disorder, and their regular usage decreases mental illnesses. For instance, in 2020, according to the National Alliance on Mental Illness (NAMI), a US-based mental health organization, 21% of adults in America were suffering from mental illness in 2020, which amounted to 52.9 million people. Therefore, an increase in the number of cases of mental illnesses is driving the growth of the psychedelic drug market.

The introduction of depression spray is the key trend gaining popularity in the psychedelic drug market. Major companies operating in the psychedelic drug market are introducing nasal-spray drugs for major depressive disorders to sustain their position in the market. For instance, in March 2019, Johnson & Johnson, a US-based company that manufactures psychedelic drugs and pharma medicines, launched a new depression spray named Spravato. The drug acts rapidly on the brain, so it starts working faster than other antidepressants. It works by restoring brain cells in patients with treatment-resistant depression.

In April 2022, Numinus, a Canada-based company that manufactures psychedelic medicine with holistic, integrated psychotherapy, acquired Novamind for a deal amount of $20.77 million. With this acquisition, Numinus is expected to expand its psychotherapy clinics in the US and develop advanced psychedelic programs. Novamind is a US-based mental health company and manufacturer of psychedelic medicine.

The countries covered in the psychedelic drug market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Table of Contents

1. Executive Summary

2. Psychedelic Drugs Market Characteristics

3. Psychedelic Drugs Market Trends And Strategies

4. Impact Of COVID-19 On Psychedelic Drugs

5. Psychedelic Drugs Market Size And Growth

• 5.1. Global Psychedelic Drugs Historic Market, 2016-2021, $ Billion
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints On The Market
• 5.2. Global Psychedelic Drugs Forecast Market, 2021-2026F, 2031F, $ Billion
  • 5.2.1. Drivers Of The Market
  • 5.2.2. Restraints On the Market

6. Psychedelic Drugs Market Segmentation

• 6.1. Global Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• Lysergic Acid Diethylamid (LSD)
• Ketamine
• Phencyclidine
• Gamma Hydroxybutyric Acid (GHB)
• Salvia
• 6.2. Global Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• Depression
• PTSD
• 6.3. Global Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• Natural
• Synthetic
• 6.4. Global Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• Treatment Resistant depression
• Opiate addiction
• Post- Traumatic stress disorder
• Narcolepsy
• Panic Disorders
• 6.5. Global Psychedelic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• Hospitals Pharmacy
• Retail Pharmacy
• Online Pharmacy

7. Psychedelic Drugs Market Regional And Country Analysis

• 7.1. Global Psychedelic Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 7.2. Global Psychedelic Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

8. Asia-Pacific Psychedelic Drugs Market

• 8.1. Asia-Pacific Psychedelic Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 8.3. Asia-Pacific Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

9. China Psychedelic Drugs Market

• 9.1. China Psychedelic Drugs Market Overview
• 9.2. China Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
• 9.3. China Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

10. India Psychedelic Drugs Market

• 10.1. India Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 10.2. India Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

11. Japan Psychedelic Drugs Market

• 11.1. Japan Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 11.2. Japan Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

12. Australia Psychedelic Drugs Market

• 12.1. Australia Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 12.2. Australia Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

13. Indonesia Psychedelic Drugs Market

• 13.1. Indonesia Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 13.2. Indonesia Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

14. South Korea Psychedelic Drugs Market

• 14.1. South Korea Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 14.2. South Korea Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

15. Western Europe Psychedelic Drugs Market

• 15.1. Western Europe Psychedelic Drugs Market Overview
• 15.2. Western Europe Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 15.3. Western Europe Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

16. UK Psychedelic Drugs Market

• 16.1. UK Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 16.2. UK Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

17. Germany Psychedelic Drugs Market

• 17.1. Germany Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 17.2. Germany Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

18. France Psychedelic Drugs Market

• 18.1. France Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 18.2. France Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

19. Eastern Europe Psychedelic Drugs Market

• 19.1. Eastern Europe Psychedelic Drugs Market Overview
• 19.2. Eastern Europe Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 19.3. Eastern Europe Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

20. Russia Psychedelic Drugs Market

• 20.1. Russia Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 20.2. Russia Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

21. North America Psychedelic Drugs Market

• 21.1. North America Psychedelic Drugs Market Overview
• 21.2. North America Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 21.3. North America Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

22. USA Psychedelic Drugs Market

• 22.1. USA Psychedelic Drugs Market Overview
• 22.2. USA Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 22.3. USA Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

23. South America Psychedelic Drugs Market

• 23.1. South America Psychedelic Drugs Market Overview
• 23.2. South America Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 23.3. South America Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

24. Brazil Psychedelic Drugs Market

• 24.1. Brazil Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 24.2. Brazil Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

25. Middle East Psychedelic Drugs Market

• 25.1. Middle East Psychedelic Drugs Market Overview
• 25.2. Middle East Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 25.3. Middle East Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

26. Africa Psychedelic Drugs Market

• 26.1. Africa Psychedelic Drugs Market Overview
• 26.2. Africa Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 26.3. Africa Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

27. Psychedelic Drugs Market Competitive Landscape And Company Profiles

• 27.1. Psychedelic Drugs Market Competitive Landscape
• 27.2. Psychedelic Drugs Market Company Profiles
  • 27.2.1. Johnson & Johnson
    • 27.2.1.1. Overview
    • 27.2.1.2. Products and Services
    • 27.2.1.3. Strategy
    • 27.2.1.4. Financial Performance
  • 27.2.2. Pfizer
    • 27.2.2.1. Overview
    • 27.2.2.2. Products and Services
    • 27.2.2.3. Strategy
    • 27.2.2.4. Financial Performance
  • 27.2.3. Hikma Pharmaceuticals PLC
    • 27.2.3.1. Overview
    • 27.2.3.2. Products and Services
    • 27.2.3.3. Strategy
    • 27.2.3.4. Financial Performance
  • 27.2.4. Roche Holding AG
    • 27.2.4.1. Overview
    • 27.2.4.2. Products and Services
    • 27.2.4.3. Strategy
    • 27.2.4.4. Financial Performance
  • 27.2.5. Merck & Co Inc
    • 27.2.5.1. Overview
    • 27.2.5.2. Products and Services
    • 27.2.5.3. Strategy
    • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Psychedelic Drugs Market

29. Psychedelic Drugs Market Future Outlook and Potential Analysis

30. Appendix

• 30.1. Abbreviations
• 30.2. Currencies
• 30.3. Research Inquiries
• 30.4. The Business Research Company
• 30.5. Copyright And Disclaimer